FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models. - O'Farrell, Marie; Duke, Greg; Crowley, Richard; Buckley, Douglas; Martins, Eduardo B.; Bhattacharya, Dipankar; Friedman, Scott L.; Kemble, George (Scientific Reports, 2022)